The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Association of MTOR Mutations With Developmental Brain Disorders, Including Megalencephaly, Focal Cortical Dysplasia, and Pigmentary Mosaicism
Open accessAbstract
IMPORTANCE: Focal cortical dysplasia (FCD), hemimegalencephaly, and megalencephaly constitute a spectrum of malformations of cortical development with shared neuropathologic features. These disorders are associated with significant childhood morbidity and mortality. OBJECTIVE: To identify the underlying molecular cause of FCD, hemimegalencephaly, and diffuse megalencephaly. DESIGN, SETTING, AND PARTICIPANTS: Patients with FCD, hemimegalencephaly, or megalencephaly (mean age, 11.7 years; range, 2-32 years) were recruited from Pediatric Hospital A. Meyer, the University of Hong Kong, and Seattle Children's Research Institute from June 2012 to June 2014. Whole-exome sequencing (WES) was performed on 8 children with FCD or hemimegalencephaly using standard-depth (50-60X) sequencing in peripheral samples (blood, saliva, or skin) from the affected child and their parents and deep (150-180X) sequencing in affected brain tissue. Targeted sequencing and WES were used to screen 93 children with molecularly unexplained diffuse or focal brain overgrowth. Histopathologic and functional assays of phosphatidylinositol 3-kinase-AKT (serine/threonine kinase)-mammalian target of rapamycin (mTOR) pathway activity in resected brain tissue and cultured neurons were performed to validate mutations. MAIN OUTCOMES AND MEASURES: Whole-exome sequencing and targeted sequencing identified variants associated with this spectrum of developmental brain disorders. RESULTS: Low-level mosaic mutations of MTOR were identified in brain tissue in 4 children with FCD type 2a with alternative allele fractions ranging from 0.012 to 0.086. Intermediate-level mosaic mutation of MTOR (p.Thr1977Ile) was also identified in 3 unrelated children with diffuse megalencephaly and pigmentary mosaicism in skin. Finally, a constitutional de novo mutation of MTOR (p.Glu1799Lys) was identified in 3 unrelated children with diffuse megalencephaly and intellectual disability. Molecular and functional analysis in 2 children with FCD2a from whom multiple affected brain tissue samples were available revealed a mutation gradient with an epicenter in the most epileptogenic area. When expressed in cultured neurons, all MTOR mutations identified here drive constitutive activation of mTOR complex 1 and enlarged neuronal size. CONCLUSIONS AND RELEVANCE: In this study, mutations of MTOR were associated with a spectrum of brain overgrowth phenotypes extending from FCD type 2a to diffuse megalencephaly, distinguished by different mutations and levels of mosaicism. These mutations may be sufficient to cause cellular hypertrophy in cultured neurons and may provide a demonstration of the pattern of mosaicism in brain and substantiate the link between mosaic mutations of MTOR and pigmentary mosaicism in skin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fast robust automated brain extraction
Smith, S. M. (2002) · Human Brain Mapping · doi:10.1002/hbm.10062 · Cited by 10,496
mTOR Signaling in Growth Control and Disease
Laplante, M., & Sabatini, D. M. (2012) · Cell · doi:10.1016/j.cell.2012.03.017 · Cited by 8,509
Laplante, M., & Sabatini, D. M. (2009) · Journal of Cell Science · doi:10.1242/jcs.051011 · Cited by 2,170
Blümcke, I., Thom, M., Aronica, E., Armstrong, D. D., Vinters, H. V., Palmini, A., Jacques, T. S., Avanzini, G., Barkovich, A. J., Battaglia, G., et al. (2011) · Epilepsia · doi:10.1111/j.1528-1167.2010.02777.x · Cited by 1,743
Self-citationThe COSMIC (Catalogue of Somatic Mutations in Cancer) database and website
Bamford, S., Dawson, E., Forbes, S., Clements, J., Pettett, R., Dogan, A., Flanagan, A., Teague, J., Futreal, P. A., Stratton, M. R., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601894 · Cited by 1,267
Bar-Peled, L., Chantranupong, L., Cherniack, A. D., Chen, W. W., Ottina, K. A., Grabiner, B. C., Spear, E. D., Carter, S. L., Meyerson, M., & Sabatini, D. M. (2013) · Science · doi:10.1126/science.1232044 · Cited by 1,080
Finding of Rare Disease Genes (FORGE) Canada Consortium, Rivière, J.-B., Mirzaa, G. M., O'Roak, B. J., Beddaoui, M., Alcantara, D., Conway, R. L., St-Onge, J., Schwartzentruber, J. A., Gripp, K. W., et al. (2012) · Nature Genetics · doi:10.1038/ng.2331 · Cited by 741
Self-citationDe novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly
Lee, J. H., Huynh, M., Silhavy, J. L., Kim, S., Dixon-Salazar, T., Heiberg, A., Scott, E., Bafna, V., Hill, K. J., Collazo, A., et al. (2012) · Nature Genetics · doi:10.1038/ng.2329 · Cited by 703
Lim, J. S., Kim, W.-I., Kang, H.-C., Kim, S. H., Park, A. H., Park, E. K., Cho, Y.-W., Kim, S., Kim, H. M., Kim, J. A., et al. (2015) · Nature Medicine · doi:10.1038/nm.3824 · Cited by 518
Defining the spectrum of international practice in pediatric epilepsy surgery patients
Harvey, A. S., Cross, J. H., Shinnar, S., Mathern, G. W., & Taskforce, T. P. E. S. S. (2008) · Epilepsia · doi:10.1111/j.1528-1167.2007.01421.x · Cited by 453
Grabiner, B. C., Nardi, V., Birsoy, K., Possemato, R., Shen, K., Sinha, S., Jordan, A., Beck, A. H., & Sabatini, D. M. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0929 · Cited by 450
Jansen, L. A., Mirzaa, G. M., Ishak, G. E., O'Roak, B. J., Hiatt, J. B., Roden, W. H., Gunter, S. A., Christian, S. L., Collins, S., Adams, C., et al. (2015) · Brain · doi:10.1093/brain/awv045 · Cited by 364
Self-citationBioImage Suite: An integrated medical image analysis suite: An update
Papademetris, X., Jackowski, M., Rajeevan, N., DiStasio, M., Okuda, H., Constable, R. T., & Staib, L. (2006) · The Insight Journal · doi:10.54294/2g80r4 · Cited by 298
Familial focal epilepsy with focal cortical dysplasia due to DEPDC5 mutations
Baulac, S., Ishida, S., Marsan, E., Miquel, C., Biraben, A., Nguyen, D. K., Nordli, D., Cossette, P., Nguyen, S., Lambrecq, V., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24368 · Cited by 293
D'Gama, A. M., Geng, Y., Couto, J. A., Martin, B., Boyle, E. A., LaCoursiere, C. M., Hossain, A., Hatem, N. E., Barry, B. J., Kwiatkowski, D. J., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24357 · Cited by 290
Self-citationSomatic Mutations in the MTOR gene cause focal cortical dysplasia type II b
Nakashima, M., Saitsu, H., Takei, N., Tohyama, J., Kato, M., Kitaura, H., Shiina, M., Shirozu, H., Masuda, H., Watanabe, K., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24444 · Cited by 196
Activation of mammalian target of rapamycin in cytomegalic neurons of human cortical dysplasia
Ljungberg, M. C., Bhattacharjee, M. B., Lu, Y., Armstrong, D. L., Yoshor, D., Swann, J. W., Sheldon, M., & D’Arcangelo, G. (2006) · Annals of Neurology · doi:10.1002/ana.20949 · Cited by 160
Mirzaa, G., Parry, D. A., Fry, A. E., Giamanco, K. A., Schwartzentruber, J., Vanstone, M. R., Logan, C. V., Roberts, N. Y., Johnson, C. A., Singh, S., et al. (2014) · Nature Genetics · doi:10.1038/ng.2948 · Cited by 158
Self-citationBar‐Peled, L., Chantranupong, L., Cherniack, A. D., Chen, W. W., Ottina, K. A., Grabiner, B. C., Spear, E. D., Carter, S. L., Meyerson, M. M., & Sabatini, D. M. (2013) · The FASEB Journal · doi:10.1096/fasebj.27.1_supplement.832.1 · Cited by 86
Hemispheric cortical dysplasia secondary to a mosaic somatic mutation in MTOR
Leventer, R. J., Scerri, T. S., Marsh, A. P. L., Pope, K., Gillies, G., Maixner, W. J., MacGregor, D. P., Harvey, A. S., Delatycki, M. B., Amor, D. J., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001594 · Cited by 84
Najm, I., Tilelli, C. Q., & Oghlakian, R. (2007) · Epilepsia · doi:10.1111/j.1528-1167.2007.01064.x · Cited by 75
Epilepsy surgery failure in children: a quantitative and qualitative analysis
Englot, D. J., Han, S. J., Rolston, J. D., Ivan, M. E., Kuperman, R. A., Chang, E. F., Gupta, N. M., Sullivan, J. E., & Auguste, K. I. (2014) · Journal of Neurosurgery Pediatrics · doi:10.3171/2014.7.peds13658 · Cited by 66
PTEN hamartoma tumour syndrome: variability of an entity
Merks, J. H. M., de Vries, L. S., Zhou, X.-P., Nikkels, P. G. J., Barth, P. G., Eng, C., & Hennekam, R. C. M. (2003) · Journal of Medical Genetics · doi:10.1136/jmg.40.10.e111 · Cited by 63
Schick, V. C., Majores, M., Engels, G., Spitoni, S., Koch, A., Elger, C. E., Simon, M., Knobbe-Thomsen, C. B., Blümcke, I., & Becker, A. J. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0128-y · Cited by 57
Wong, M. (2011) · Experimental Neurology · doi:10.1016/j.expneurol.2011.10.002 · Cited by 56
Focal Cortical Dysplasia and Epilepsy Surgery
Lee, S. K., & Kim, D. W. (2013) · Journal of Epilepsy Research · doi:10.14581/jer.13009 · Cited by 55
Elia, M., Amato, C., Bottitta, M., Grillo, L., Calabrese, G., Esposito, M., & Carotenuto, M. (2012) · Brain and Development · doi:10.1016/j.braindev.2012.03.005 · Cited by 44
Preliminary Functional Assessment and Classification ofDEPDC5Variants Associated with Focal Epilepsy
van Kranenburg, M., Hoogeveen‐Westerveld, M., & Nellist, M. D. (2014) · Human Mutation · doi:10.1002/humu.22723 · Cited by 34
Sabatini, D. M., Grabiner, B. C., Nardi, V., et al. (2014) · PMC · Cited by 29
Mystery Case: Cowden syndrome presenting with partial epilepsy related to focal cortical dysplasia
Child, N. D., & Cascino, G. D. (2013) · Neurology · doi:10.1212/wnl.0b013e3182a55ef0 · Cited by 27
O’Rourke, D., Twomey, E., Lynch, S. A., & King, M. D. (2012) · Clinical Dysmorphology · doi:10.1097/mcd.0b013e328351639d · Cited by 24
Hemimegalencephaly in a Patient With a Neurocutaneous Syndrome
Chapman, K. E., & Cárdenas, J. F. (2008) · Seminars in Pediatric Neurology · doi:10.1016/j.spen.2008.10.010 · Cited by 19
Auriemma, A., Agostinis, C., Bianchi, P., et al. (2000) · European Journal of Ultrasound · doi:10.1016/s0929-8266(00)00099-9 · Cited by 18
Hypomelanosis of Ito with hemimegalencephaly
Sharma, S., Sankhyan, N., Kabra, M., et al. (2009) · Dermatology Online Journal · doi:10.5070/d36324c2ww · Cited by 14
Cited by
Spatiotemporal gene expression trajectories reveal developmental hierarchies of the human cortex
Nowakowski, T. J., Bhaduri, A., Pollen, A. A., Alvarado, B., Mostajo-Radji, M. A., Di Lullo, E., Haeussler, M., Sandoval-Espinosa, C., Liu, S. J., Velmeshev, D., et al. (2017) · Science · doi:10.1126/science.aap8809 · Cited by 964
Self-citationAttacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer
Yu, L., Wei, J., & Liu, P. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.06.019 · Cited by 763
mTOR: Role in cancer, metastasis and drug resistance
Murugan, A. K. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.003 · Cited by 483
Molecular neurobiology of mTOR
Switon, K., Kotulska, K., Janusz-Kaminska, A., Zmorzynska, J., & Jaworski, J. (2017) · Neuroscience · doi:10.1016/j.neuroscience.2016.11.017 · Cited by 387
Najm, I., Lal, D., Alonso Vanegas, M., Cendes, F., Lopes‐Cendes, I., Palmini, A., Paglioli, E., Sarnat, H. B., Walsh, C. A., Wiebe, S., et al. (2022) · Epilepsia · doi:10.1111/epi.17301 · Cited by 361
Self-citation
Metadata
- Authors
- Mirzaa, G. M., Campbell, C. D., Solovieff, N., Goold, C. P., Jansen, L. A., Menon, S., Timms, A. E., Conti, V., Biag, J. D., Olds, C., Boyle, E. A., Collins, S., Ishak, G., Poliachik, S. L., Girisha, K. M., Yeung, K.-S., Chung, B. H. Y., Rahikkala, E., Gunter, S. A., McDaniel, S. S., Macmurdo, C. F., Bernstein, J. A., Martin, B., Leary, R. J., Mahan, S., Liu, S., Weaver, M., Dorschner, M. O., Jhangiani, S., Muzny, D. M., Boerwinkle, E., Gibbs, R. A., Lupski, J. R., Shendure, J., Saneto, R. P., Novotny, E. J., Wilson, C. J., Sellers, W. R., Morrissey, M. P., Hevner, R. F., Ojemann, J. G., Guerrini, R., Murphy, L. O., Winckler, W., & Dobyns, W. B.
- Venue
- JAMA Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2016-07-01
- Volume
- 73
- Issue
- 7
- Pages
- 836
- ISSN
- 2168-6149 (ISSN-L)
- OpenAlex
- W2347029403
- Cited by
- 273
- References
- 34
- FWCI
- 36.01
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.